Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/39339
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSomogyi, A.en
dc.contributor.authorBochner, F.en
dc.contributor.authorFoster, D.en
dc.date.issued2004en
dc.identifier.citationAustralian Prescriber, 2004; 27(2):47-49en
dc.identifier.issn0312-8008en
dc.identifier.issn1839-3942en
dc.identifier.urihttp://hdl.handle.net/2440/39339-
dc.descriptionReproduced with permission from Australian Prescriber The document attached has been archived with permission from the publisher/copyright holder.en
dc.description.abstractChiral drugs are made up of molecules with the same chemical structure, but different three-dimensional arrangements. Modern manufacturing has enabled the development of products containing a single molecular arrangement. The development of these single enantiomers from chiral drugs is known as chiral switching. Enantiomers of the same drug can have different pharmacodynamic and pharmacokinetic properties. This may translate into potential health benefits, such as an improved safety margin, if one of the enantiomers has more favourable therapeutic and pharmacokinetic characteristics. However, some chiral switching has resulted in unpredicted toxicity and the withdrawal of the enantiomer from the market or a halt in its development. Drug companies are increasingly using chiral switching as a marketing strategy, but before prescribers switch to single enantiomer drugs they should look for evidence from well-conducted clinical trials that shows the chiral switch is cost-effective and improves the outcomes for patients rather than patents.en
dc.description.statementofresponsibilityA. Somogyi, F. Bochner and D. Fosteren
dc.language.isoenen
dc.publisherAustralian Prescriberen
dc.rights© 2004 Australian Prescriberen
dc.source.urihttp://www.australianprescriber.com/magazine/27/2/47/9/en
dc.subjectEnantiomers; drug industry; pharmacokinetics; adverse effectsen
dc.titleInside the isomers: the tale of chiral switchesen
dc.typeJournal articleen
dc.identifier.rmid0020071934en
dc.identifier.doi10.18773/austprescr.2004.039en
dc.identifier.pubid48027-
pubs.library.collectionPharmacology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidSomogyi, A. [0000-0003-4779-0380]en
dc.identifier.orcidFoster, D. [0000-0002-7345-4084]en
Appears in Collections:Pharmacology publications

Files in This Item:
File Description SizeFormat 
hdl_39339.pdf54.6 kBPublisher's PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.